Nitric oxide-donating aspirin (NCX 4016) inhibits neointimal thickening in a pig model of saphenous vein-carotid artery interposition grafting: a comparison with aspirin and morpholinosydnonimine (SIN-1).

@article{Wan2007NitricOA,
  title={Nitric oxide-donating aspirin (NCX 4016) inhibits neointimal thickening in a pig model of saphenous vein-carotid artery interposition grafting: a comparison with aspirin and morpholinosydnonimine (SIN-1).},
  author={Song Wan and Nilima Shukla and Gianni Angelini and Anthony P.C. Yim and Jason L Johnson and Jamie Yancey Jeremy},
  journal={The Journal of thoracic and cardiovascular surgery},
  year={2007},
  volume={134 4},
  pages={1033-9}
}
OBJECTIVE Despite its proven value in reducing thrombotic complications in patients undergoing coronary artery bypass graft surgery, aspirin does not reduce the incidence of late vein graft failure. It was suggested, therefore, that co-administration of nitric oxide with aspirin may compensate for these limitations. A drug class that fulfills this pharmacologic criterion is nitric oxide-donating aspirin (NCX 4016). METHODS The effect of administration of the aspirin-nitric oxide adduct, NCX… CONTINUE READING